MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotype
- aCentre International de Recherche en Infectiologie, INSERM U1111-CNRS UMR5308, 69365 Lyon Cedex 07, France;
- bCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702;
- cLeidos Biomedical Research, Inc., Frederick, MD 21702;
- dCenter for Infection and Immunity of Lille, Institut Pasteur de Lille, INSERM U1019, F-59000 Lille, France;
- eCenter for Infection and Immunity of Lille, University of Lille, F-59000 Lille, France;
- fUMR 8204, Centre National de la Recherche Scientifique, F-59000 Lille, France;
- gU1019, Team 7, Equipe Fondation pour la Recherche Médicale, Institut National de la Santé et de la Recherche Médicale, F-59000 Lille, France;
- hCentre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, INSERM 1052, CNRS 5286, 69008 Lyon, France;
- iUniversity of Lyon, Université Claude Bernard Lyon 1, 69008 Lyon, France;
- jTransforming Growth Factor-b and Immune-Evasion Group, German Cancer Research Center, 69120 Heidelberg, Germany;
- kDepartment of Clinical Microbiology, Hospices Civils de Lyon, 69002 Lyon, France;
- lInflammation Research Center, Department of Biomedical Molecular Biology, Ghent University, Flanders Institute for Biotechnology, 9000 Ghent, Belgium;
- mChronic Inflammation and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany
See allHide authors and affiliations
Edited by Lora V. Hooper, University of Texas Southwestern Medical Center, Dallas, TX, and approved August 16, 2018 (received for review January 4, 2018)

Significance
Growing evidence suggests that prominent changes in the gut microbial communities (dysbiosis) play a key role in the development of allergic disorders, but the underlying mechanisms remain largely unknown. Here, we used a murine model of human allergic contact dermatitis to demonstrate a regulatory role of the adaptor mitochondrial antiviral signaling (MAVS) RIG-I–like receptors on disease outcome by modulating gut barrier function and bacterial ecology. Our results highlight an unexpected role of the RIG-I–MAVS pathway in maintenance of intestinal barrier function and modulation of gut commensal flora to prevent the development of inflammatory diseases such as allergy. These data provide a rationale for manipulating the gut microbiota as a therapeutic intervention in subjects at risk of developing allergy.
Abstract
Prominent changes in the gut microbiota (referred to as “dysbiosis”) play a key role in the development of allergic disorders, but the underlying mechanisms remain unknown. Study of the delayed-type hypersensitivity (DTH) response in mice contributed to our knowledge of the pathophysiology of human allergic contact dermatitis. Here we report a negative regulatory role of the RIG-I–like receptor adaptor mitochondrial antiviral signaling (MAVS) on DTH by modulating gut bacterial ecology. Cohousing and fecal transplantation experiments revealed that the dysbiotic microbiota of Mavs−/− mice conferred a proallergic phenotype that is communicable to wild-type mice. DTH sensitization coincided with increased intestinal permeability and bacterial translocation within lymphoid organs that enhanced DTH severity. Collectively, we unveiled an unexpected impact of RIG-I–like signaling on the gut microbiota with consequences on allergic skin disease outcome. Primarily, these data indicate that manipulating the gut microbiota may help in the development of therapeutic strategies for the treatment of human allergic skin pathologies.
Footnotes
↵1Present address: MaaT Pharma, 69007 Lyon, France.
↵2A.D. and M.C. contributed equally to this work.
↵3Present address: Department of Immunity, Virus and Infammation (IVI), Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France.
- ↵4To whom correspondence should be addressed. Email: marie-cecile.michallet{at}lyon.unicancer.fr.
Author contributions: E.P., S.D., O.D., M.P., G.L., J.M., and M.-C.M. designed research; E.P., A.D., S.D., L.M., L.B., M.G., C.M., D.B., J.-P.R., S.L., M.P., E.K., A.C., C.B., U.R., M.H., and M.-C.M. performed research; E.P., S.D., O.D., M.P., G.L., J.M., and M.-C.M. analyzed data; and E.P., A.D., M.C., A.B.-B., J.C.M., C.C., G.T., J.M., and M.-C.M. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1722372115/-/DCSupplemental.
Published under the PNAS license.
Citation Manager Formats
Article Classifications
- Biological Sciences
- Immunology and Inflammation